Management of Refractory Platelet Transfusions

Patients who do not respond to platelet transfusions should be evaluated to ensure that their platelet counts are increasing adequately. The best way to do this is by taking a blood sample one or two hours after the transfusion. If the patient’s platelet counts are still low, further investigation is necessary. However, it is not appropriate to request HLA-matched platelets or a directed platelet donation at this stage.

Continuing to give random platelet transfusions is also not recommended. Platelets are necessary for the patient’s recovery, but it is important to determine why the transfusions are not working. Therefore, checking for HLA antibodies is the next step in the management of refractory platelet transfusions. Once the cause of the refractory response is identified, appropriate treatment can be initiated.

In summary, managing refractory platelet transfusions involves evaluating the patient’s response to the transfusions, checking for HLA antibodies, and determining the underlying cause of the refractory response. Platelets are still necessary for the patient’s recovery, but it is important to address the underlying issue to ensure that the transfusions are effective.

Diagnostic Investigations for Non-Hodgkin’s Lymphoma

Non-Hodgkin’s lymphoma is a type of cancer that affects the lymphatic system. There are several diagnostic investigations that can be used to diagnose this condition.

Excisional Biopsy of an Enlarged Lymph Node: This is the most common diagnostic investigation for suspected non-Hodgkin’s lymphoma. It involves removing all of the abnormal tissue from an enlarged lymph node.

Computed Tomography (CT) of the Chest, Neck, Abdomen, and Pelvis: CT scanning can indicate features suggestive of lymphoma, such as lymphadenopathy and hepatosplenomegaly. However, it cannot provide a tissue diagnosis.

Core Needle Biopsy of an Enlarged Lymph Node: If a surgical excisional biopsy is not appropriate, a core needle biopsy can be performed. However, if this does not reveal a definite diagnosis, then an excisional biopsy should be undertaken.

Full Blood Count: A full blood count can be a helpful first-line investigation if a haematological malignancy is suspected, but it is not sufficient to be diagnostic for non-Hodgkin’s lymphoma.

Protein Electrophoresis and Urine Bence-Jones Protein: Protein electrophoresis can be helpful in screening for multiple myeloma, but it is not helpful for diagnosing non-Hodgkin’s lymphoma.

In conclusion, a combination of these diagnostic investigations can be used to diagnose non-Hodgkin’s lymphoma. However, excisional biopsy remains the gold standard for diagnosis.

Understanding Iron Deficiency Anaemia and Treatment Options

Iron deficiency anaemia is a common condition that can present with symptoms such as lethargy, tiredness, and shortness of breath on exertion. It is often seen in women due to menstruation and blood loss associated with it, as well as in pregnant women. However, it is not a common finding in men and should be investigated further if present.

Treatment for iron deficiency anaemia involves the use of ferrous sulfate, typically at a dose of 200 mg two to three times a day for at least three months. Blood tests should be repeated after this time to assess the effectiveness of therapy. Folic acid supplementation may also be necessary in cases of folate deficiency anaemia, which presents with a raised MCV.

It is important to investigate persistent anaemia despite adequate iron supplementation, as it may indicate an underlying malignancy. Men with unexplained iron deficiency anaemia and a haemoglobin level of < 110 g/l should be referred urgently to the gastroenterology team for investigation of upper or lower gastrointestinal malignancy. Overall, understanding the causes and treatment options for iron deficiency anaemia can help improve patient outcomes and prevent complications.

Causes and Symptoms of Vitamin B12 Deficiency

Vitamin B12 deficiency can lead to macrocytic anaemia and neurological symptoms. The most common cause of this deficiency is the presence of anti-intrinsic factor antibodies. Intrinsic factor is necessary for the absorption of dietary vitamin B12 in the terminal ileum. Without it, vitamin B12 cannot be absorbed, leading to deficiency and anaemia. Symptoms of vitamin B12 deficiency include fatigue, lethargy, dyspnoea on exertion, and neurological symptoms such as peripheral loss of vibration and proprioception, weakness, and paraesthesiae. If left untreated, it can lead to hepatosplenomegaly, heart failure, and demyelination of the spinal cord, causing ataxia.

Diagnosis can be made with a vitamin B12 level test, which reveals anaemia, often pancytopenia, and a raised MCV. A blood film reveals hypersegmented neutrophils, megaloblasts, and oval macrocytes. Treatment involves replacement of vitamin B12.

Other possible causes of vitamin B12 deficiency include intestinal tapeworm, which is rare, and gastrointestinal malignancy, which causes iron deficiency anaemia with a low MCV. Destruction of the anterior and lateral horns of the spinal cord describes anterolateral sclerosis (ALS), which is characterised by progressive muscle weakness and would not cause anaemia or loss of sensation. Enlargement of the ventricles on head CT indicates hydrocephalus, which could explain the wide-based gait but not the anaemia and other symptoms. A haemoglobin A1c of 12.2% is associated with diabetes, which could explain decreased peripheral sensation to fine touch but would not be associated with megaloblastic anaemia.

DDAVP for Increasing von Willebrand Factor

DDAVP is a medication that can be administered to increase the amount of von Willebrand factor in the body, which is necessary for surgical or dental procedures. This medication can increase plasma von Willebrand factor and factor VIII concentrations by two to five times. The mechanism of action involves the induction of cyclic adenosine monophosphate (cAMP)-mediated vWF secretion through a direct effect on endothelial cells. Overall, DDAVP is a useful tool for increasing von Willebrand factor levels in the body, allowing for safer and more successful surgical and dental procedures.

Symptoms and Diagnosis of Hyperprolactinaemia

Hyperprolactinaemia is a condition characterized by elevated levels of prolactin in the body. This condition is typically associated with symptoms such as milk production, decreased libido, and absence of menstruation. However, visual disturbances are not always present, as many cases of hyperprolactinaemia are related to a microprolactinoma.

When diagnosing hyperprolactinaemia, it is important to assess thyroid status as this condition is often associated with hypothyroidism. Thyroxine levels are usually low in individuals with hyperprolactinaemia. Additionally, beta-HCG levels are elevated in pregnancy, so it is important to rule out pregnancy as a potential cause of elevated prolactin levels.

In summary, hyperprolactinaemia is a condition that can present with a variety of symptoms, but is typically characterized by elevated prolactin levels. Diagnosis involves assessing thyroid status and ruling out pregnancy as a potential cause.

Pathophysiological Mechanisms of Various Medical Conditions

Haemophilia: Deficiency of a Clotting Factor in the Intrinsic Pathway of Coagulation
Haemophilia is an X-linked recessive condition that affects the intrinsic pathway of coagulation. It is caused by a mutation in factor VIII or IX, leading to deficient coagulation. Patients present with excessive bleeding, such as spontaneous bruising, prolonged bleeding following a dental procedure or minor injury, bleeding into the joints (haemarthrosis), and epistaxis. Treatment involves correcting the deficiency with concentrated factor VIII or IX.

Von Willebrand’s Disease: Deficiency of a Protein Found in Endothelial Cells and Released by Endothelial Damage
Von Willebrand’s disease is an autosomal dominant, inherited bleeding disorder caused by a deficiency of the von Willebrand factor. This protein is found in the endothelial cells lining the vessels and is released following endothelial damage. It promotes adhesion of platelets to the area of damage and stabilizes factor VIII, both actions promoting haemostasis. Symptoms include easy bruising and prolonged bleeding following minimal trauma.

Ewing’s Sarcoma: Translocation Between Chromosomes 11 and 22
Ewing’s sarcoma is a malignant bone tumour seen in children and young adults. It is caused by a translocation between chromosomes 11 and 22.

Leukaemia: Invasion of Bone Marrow by Leukaemic Cells
Leukaemia is a type of cancer that affects the blood and bone marrow. It is caused by the invasion of bone marrow by leukaemic cells, leading to pancytopenia, a condition in which there is a deficiency of all three types of blood cells: red blood cells, white blood cells, and platelets. Symptoms include fatigue, weakness, shortness of breath, and increased susceptibility to infections. Treatment involves chemotherapy, radiation therapy, and bone marrow transplantation.

Partial remission occurs when a patient meets all the criteria for complete remission except for having more than 5% bone marrow blasts. To be diagnosed with partial remission, the blast cells can be between 5% and 25% and must have decreased by at least 50% from their levels before treatment.

Complete remission is achieved when a patient meets specific criteria, including having a neutrophil count of over 1.0 × 109/l and a platelet count of over 100 × 109/l, not requiring red cell transfusions, having normal cellular components on bone marrow biopsy, having less than 5% blasts in the bone marrow without Auer rods present, and having no signs of leukemia anywhere else in the body.

Complete remission with incomplete recovery is when a patient meets all the criteria for complete remission except for continuing to have neutropenia or thrombocytopenia.

Resistant disease occurs when a patient fails to achieve complete or partial remission and still has leukemia cells in their peripheral blood or bone marrow seven days after completing initial therapy.

A morphologic leukemia-free state is when a patient has less than 5% bone marrow blasts without blasts with Auer rods present and no extramedullary disease, but they do not meet the criteria for neutrophils, platelets, and blood transfusions.

Understanding Myelofibrosis: A Comparison with Other Bone Marrow Disorders

Myelofibrosis is a rare disorder that primarily affects older patients. It is characterized by bone marrow failure, which can also be found in other diseases such as advanced prostate cancer, acute lymphoblastic leukemia, acute myelocytic leukemia, and chronic myeloid leukemia. However, myelofibrosis can be distinguished from these other disorders by specific diagnostic clues.

One of the key diagnostic features of myelofibrosis is the presence of a leukoerythroblastic picture with teardrop-shaped red blood cells, which is also seen in advanced prostate cancer. However, in myelofibrosis, a failed bone marrow aspirate, or dry tap, is frequent and a bone marrow trephine biopsy is needed for diagnosis. This is not the case in other bone marrow disorders.

Myelofibrosis is caused by the proliferation of megakaryocytes, which leads to intense bone marrow fibrosis, marrow failure, and secondary hepatosplenomegaly due to extramedullary hematopoiesis. Patients may present with systemic upset, symptoms of marrow failure, or abdominal discomfort from hepatosplenomegaly. Treatment is supportive, with bone marrow transplant reserved for younger patients. The median survival is 4-5 years, and transformation to acute myeloid leukemia is relatively common.

In contrast, acute lymphoblastic leukemia is a disease of childhood that presents with elevated white cell count and blasts on peripheral blood film. Acute myelocytic leukemia and chronic myeloid leukemia both present with raised white cell counts and blasts on blood film, but are more common in younger patients. Advanced prostate cancer may cause bone marrow failure if there is replacement of enough bone marrow by metastases, but patients would also complain of bone pain.

In summary, while bone marrow failure may be found in various diseases, specific diagnostic clues such as a leukoerythroblastic picture with teardrop-shaped red blood cells and a failed bone marrow aspirate can help distinguish myelofibrosis from other bone marrow disorders.

The Effect of Fresh Blood on Haemoglobin Levels

When one unit of fresh blood is transfused, it increases the haemoglobin levels in the body by approximately 10 g/L. This is equivalent to the effect of one unit of red cell concentrate. Both fresh blood and red cell concentrate contain red blood cells, which are responsible for carrying oxygen throughout the body. Therefore, the increase in haemoglobin levels is due to the additional red blood cells that are introduced into the bloodstream. This information is important for medical professionals who need to monitor and manage the haemoglobin levels of their patients, particularly those who have undergone significant blood loss or have conditions that affect their red blood cell count.